Stockreport

Cellular Biomedicine Group Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology to Treat  Solid Tumors

CELLULAR BIOMEDICINE GROUP INC  (CBMG) 
Last cellular biomedicine group inc earnings: 11/6 04:25 pm Check Earnings Report
US:NASDAQ Investor Relations: cellbiomedgroup.com/investor-relations
PDF SHANGHAI, China and CUPERTINO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage bio [Read more]